Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variants
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The SARS-CoV-2 vaccine BBV152/Covaxin is well-tolerated and was shown to be 77.8% efficacious against symptomatic and 93.4% efficacious against severe symptomatic COVID-19 disease in adults. Previous studies have shown that sera from Covaxin vaccinated individuals have neutralizing activity against B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), B.1.1.28 (Zeta), and B.1.617.1 (Kappa) SARS-CoV-2 variants. The B.1.1.529 variant (Omicron) recently emerged in November 2021 and has spread throughout the world. The Omicron variant has more than 30 mutations within the spike protein that could impact vaccine-mediated immunity. We used a live virus neutralization assay to evaluate the neutralizing activity against the Omicron variant of sera collected from subjects who received a booster dose (6-month after primary series last dose) of Covaxin. We found that sera from Covaxin boosted individuals showed neutralizing activity against D614G (vaccine strain), Delta, and Omicron variants. One hundred percent of boosted subjects showed neutralizing activity against the Delta variant while over 90% of boosted subjects showed neutralizing activity against the Omicron variant. These findings show that a booster dose of Covaxin can generate robust neutralizing antibody responses against the Omicron variant.
Article activity feed
-
SciScore for 10.1101/2022.01.24.22269189: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization In the ongoing phase 2 trial (ClinicalTrials.gov: NCT04471519) the protocol was amended after six months to re-consent and randomize previously vaccinated participants to receive a third dose (booster) of Covaxin on Day 215. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Cells were incubated with an anti-SARS-CoV spike primary antibody directly conjugated to Alexa-flour-647 (CR3022-AF647) overnight at 4°C. anti-SARS-CoV spikesuggested: NoneExperimental Models: Cell Lines Sentences Resources The D614G, B.1.617.2, and B.1.1.529 viruses were … SciScore for 10.1101/2022.01.24.22269189: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization In the ongoing phase 2 trial (ClinicalTrials.gov: NCT04471519) the protocol was amended after six months to re-consent and randomize previously vaccinated participants to receive a third dose (booster) of Covaxin on Day 215. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Cells were incubated with an anti-SARS-CoV spike primary antibody directly conjugated to Alexa-flour-647 (CR3022-AF647) overnight at 4°C. anti-SARS-CoV spikesuggested: NoneExperimental Models: Cell Lines Sentences Resources The D614G, B.1.617.2, and B.1.1.529 viruses were isolated and propagated on Vero-TMPRSS2 cells as previously described. Vero-TMPRSS2suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)The antibody-virus mixture was added to VeroE6-TMPRSS2 cells and incubated at 37°C for 1 hour. VeroE6-TMPRSS2suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Software and Algorithms Sentences Resources The FRNT50 titers were interpolated using a 4-parameter nonlinear regression in GraphPad Prism 9.2.0. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04471519 Active, not recruiting Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COV… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
